

07 Jul 2024 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: US approval for Lilly's Alzheimer's contender; the challenges and rewards of late-stage ADCs; Eisai regains control of ADC from BMS; RSV vaccine developers hit by declining expectations; and an interview with Amgen's Ian Thompson.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 5 July 2024, including: US approval for [Eli Lilly and Company's](#) Alzheimer's contender; the challenges and rewards of late-stage ADCs; [Eisai Co., Ltd.](#) regains control of ADC from [Bristol Myers Squibb Company](#); RSV vaccine developers hit by declining expectations; and an interview with [Amgen, Inc.](#)'s Ian Thompson.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Lilly's Kisunla Set To Give Leqembi A Run For Its Money In Early Alzheimer's](#)" - Scrip, 2 Jul, 2024.)

(Also see "[Big Pharma Leads Development Of Novel Antibody-Drug Conjugates](#)" - Scrip, 28 Jun, 2024.)

(Also see "[Eisai Regains Full Control Of ADC Program After Bristol R&D Reprioritization](#)" - Scrip, 1 Jul, 2024.)

# SCRIP

CITELINE COMMERCIAL

(Also see "[Moderna And GSK Hit By Declining RSV Vaccines Expectations](#)" - Scrip, 28 Jun, 2024.)

(Also see "[Amgen's Ian Thompson On Payer Shifts, Obesity Opportunity And The Future Of Blockbusters](#)" - Scrip, 28 Jun, 2024.)

[Click here to explore this interactive content online](#) 